BioCentury
ARTICLE | Distillery Therapeutics

Cancer

November 27, 2017 7:02 PM UTC

Cell culture and mouse studies suggest the GLS inhibitor CB-839 could help treat KRAS-mutant lung cancers that also harbor KEAP1 mutations. In a mouse model of KRAS- and KEAP1-mutant lung cancer, the GLS inhibitor CB-839 decreased tumor burden compared with vehicle, whereas in a mouse model of KRAS-mutant, KEAP1 wild-type lung cancer, CB-839 had no effect on tumor burden. In patient-derived xenograft (PDX) mouse models of lung cancer harboring KRAS and KEAP1 mutations, but not in PDX models of KRAS-mutant, KEAP1 wild-type lung cancer, CB-839 decreased tumor burden. Next steps could include investigating whether KRAS and KEAP1 mutation status predicts responses to CB-839 in clinical trials...